keyword
MENU ▼
Read by QxMD icon Read
search

non-small cell lung cancer

keyword
https://www.readbyqxmd.com/read/29909581/switch-maintenance-therapy-with-docetaxel-and-bevacizumab-after-induction-therapy-with-cisplatin-pemetrexed-and-bevacizumab-in-advanced-non-squamous-non-small-cell-lung-cancer-a-phase-ii-study
#1
Koji Nishimoto, Masato Karayama, Naoki Inui, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Nao Inami, Shun Matsuura, Yusuke Kaida, Takashi Matsui, Kazuhiro Asada, Hiroyuki Matsuda, Masato Fujii, Mikio Toyoshima, Shiro Imokawa, Takafumi Suda
Switch maintenance therapy, using alternative agents that were not administered during induction chemotherapy, is a treatment option for advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab is known to increase the efficacy of other chemotherapeutic agents; however, switch maintenance therapy with docetaxel and bevacizumab has not been adequately studied. The goal of this study was to evaluate the efficacy and safety of switch maintenance therapy with docetaxel and bevacizumab following induction therapy with cisplatin, pemetrexed, and bevacizumab...
June 16, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29909489/ets1-regulates-twist1-transcription-in-a-kras-g12d-lkb1-metastatic-lung-tumor-model-of-non-small-cell-lung-cancer
#2
Guetchyn Millien, Yuxia Cao, Carl J O'Hara, Jean-Bosco Tagne, Anne Hinds, Mary C Williams, Maria I Ramirez, Hasmeena Kathuria
Distinct members of the Ets family of transcription factors act as positive or negative regulators of genes involved in cellular proliferation, development, and tumorigenesis. In human lung cancer, increased ETS1 expression is associated with poor prognosis and metastasis. We tested whether ETS1 contributes to lung tumorigenesis by binding to Twist1, a gene involved in tumor cell motility and dissemination. We used a mouse lung cancer model with metastasis driven by conditionally activated Kras and concurrent tumor suppressor Lkb1 loss (Kras G12D / Lkb1-/- model) and a similar model of lung cancer that does not metastasize, driven by conditionally activated Kras alone (Kras G12D model)...
June 16, 2018: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/29909007/early-emergence-of-de-novo-egfr-t790-m-gatekeeper-mutations-during-erlotinib-treatment-in-pc9-non-small-cell-lung-cancer-cells
#3
Sujin Kim, Angela Kj Park, Jeonghee Cho
The emergence of the T790 M gatekeeper mutation in the Epidermal Growth Factor Receptor (EGFR) gene is an important mechanism that can lead to the acquired resistance to EGFR-targeted tyrosine kinase inhibitors such as erlotinib or gefitinib. These drugs have been used in treating a subset of non-small cell lung cancer (NSCLC) patients harboring EGFR activating mutations. Here we investigated the paths leading to the acquisition of the T790 M mutation by establishing an erlotinib resistant PC9 cell model harboring ectopically introduced EGFR cDNA...
June 14, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29908981/clinical-mis-stagings-and-risk-factors-of-occult-nodal-disease-in-non-small-cell-lung-cancer
#4
Adam R Dyas, Robert W King, Asem F Ghanim, Robert J Cerfolio
BACKGROUND: Our objective is to compare the clinical to the pathologic stage in patients with non-small cell lung cancer (NSCLC). METHODS: Review of a prospective database from one surgeon. Patients had NSCLC, chest tomography (CT) and most had positron emissions tomography (PET). Those with suggested N1, N2, central tumors and/or tumors > 5 cm underwent mediastinoscopy and/or endobronchial ultrasound and, if N2 negative, underwent resection with complete thoracic lymphadenectomy...
June 14, 2018: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29908871/an-overview-on-personalisation-of-radiotherapy-prescriptions-in-locally-advanced-non-small-cell-lung-cancer-are-we-there-yet
#5
REVIEW
Sarah Barrett, Gerard G Hanna, Laure Marignol
Standard of care radiotherapy in LA-NSCLC is 60-66 Gy in 30-33 fractions. However outcomes for these patients are poor with 5-year survival in the range of 10-20%. Randomised controlled trials have shown that dose escalation in a linear fashion does not improve outcomes for all patients, thus there is a need to tailor the prescription to the individual patient. This review assesses the strategies published to personalise the radiation therapy dose prescription in LA-NSCLC. A systematic and scoping search of the literature was performed to identify studies that met the inclusion criteria...
June 13, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29908788/prophylactic-cranial-irradiation-in-extensive-stage-small-cell-lung-cancer-outcomes-at-a-comprehensive-cancer-centre
#6
Andrew Bang, Wayne S Kendal, Scott A Laurie, Graham Cook, Robert M MacRae
PURPOSE: The role of prophylactic cranial irradiation (PCI) remains controversial in extensive stage small cell lung cancer (ES-SCLC) with the publication of 2 randomized control trials demonstrating differing outcomes in overall survival. The aim of this study is to determine the impact of PCI on survival and the development of brain metastasis while addressing the disparate use of postchemotherapy brain imaging in the aforementioned trials. METHODS AND MATERIALS: The medical records of 397 consecutive patients with ES-SCLC between Jan...
May 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29908438/targeting-rna-polymerase-i-transcription-machinery-in-cancer-cells-by-a-novel-monofunctional-platinum-based-agent
#7
Zhen-Lei Zhang, Chun-Lai Zhao, Qian Chen, Kai Xu, Xin Qiao, Jing-Yuan Xu
Aberrant ribosome biogenesis and enlarged nucleoli have long been used by pathologists as a marker of aggressive tumors. Suppression of RNA polymerase I (Pol I) transcription machinery within the nucleolus could be a direct way to trigger the nucleolar stress and to inhibit the rapid proliferation of cancer cells. Here we modified cisplatin with an analogue of the selective inhibitor of RNA polymerase I-mediated transcription BMH-21 to develop a novel platinum-based Pol I selective inhibitor. We show that this novel monofunctional platinum-based agent, P1-B1, had enhanced antitumor activity of up to 17-fold greater than the clinical drug cisplatin in cisplatin-resistant non-small cell lung cancer cells...
June 1, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29908299/construction-and-biological-evaluation-of-different-self-assembled-nanoarchitectures-of-fzu-03-010
#8
Tingting Lv, Liang Xu, Guolin Wu, Cailong Li, Yibo Wen, Tao Zhang, Haijun Chen, Yu Gao
Chemotherapy is currently one of the promising therapeutic methods for non-small-cell lung cancer (NSCLC), but the emergence of multidrug resistance (MDR) is the greatest obstacle to efficient drug delivery for successful chemotherapy. Nanotechnology-based drug delivery holds great promise to promote intracellular drug delivery to reverse MDR. In this work, we used our previously synthesized ursolic acid (UA) derivative, FZU-03,010 (F3), to prepare nanodrugs of F3 with different architectures and study the role of the structure on the physiochemical properties and the biological effects against A549 and its PTX-resistant A549/PTX lung cancer cells...
June 13, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29908210/the-tgf%C3%AE-induced-lncrna-tbila-promotes-non-small-cell-lung-cancer-progression-in-vitro-and-in-vivo-via-cis-regulating-hgal-and-activating-s100a7-jab1-signaling
#9
Zhiliang Lu, Yuan Li, Yun Che, Jianbing Huang, Shouguo Sun, Shuangshuang Mao, Yuanyuan Lei, Ning Li, Nan Sun, Jie He
Long non-coding RNAs (lncRNAs) play critical roles in multiple cellular processes in non-small cell lung cancer (NSCLC); however, the involvement of lncRNAs in the transforming growth factor-beta (TGFβ) signaling pathway, the critical tumor cell epithelial-mesenchymal transition (EMT) and metastasis pathway, remains poorly understood. To address this issue, we compared the lncRNAs expression patterns of NSCLC cells treated with and without TGFβ1 treatment. We observed that one of the most prominent hits, TGFβ-induced lncRNA (TBILA), promoted NSCLC progression and was upregulated in tumor tissues...
June 13, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29908090/drug-resistance-profiles-of-mutations-in-the-ret-kinase-domain
#10
Xuan Liu, Tao Shen, Blaine H M Mooers, Frank Hilberg, Jie Wu
BACKGROUND AND PURPOSE: RET alterations are found in thyroid and lung cancer. While RET tyrosine kinase inhibitors (TKIs) are used to treat thyroid cancer and are in clinical trials for RET fusion-positive non-small cell lung cancer (NSCLC), the impact of mutations in the RET kinase domain on drug sensitivity was largely uncharacterized. EXPERIMENTAL APPROACH: We identified and analyzed mutations in the RET kinase domain that conferred resistance to the TKIs cabozantinib, lenvatinib, vandetanib, and nintedanib using RET kinase-dependent BaF3/KIF5B-RET (BaF3/KR) cells...
June 16, 2018: British Journal of Pharmacology
https://www.readbyqxmd.com/read/29907952/bim-deletion-polymorphism-confers-resistance-to-osimertinib-in-egfr-t790m-lung-cancer-a-case-report-and-literature-review
#11
REVIEW
Xuanzong Li, Shijiang Wang, Butuo Li, Zhen Wang, Shuheng Shang, Yang Shao, Xindong Sun, Linlin Wang
The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. However, resistance inevitably occurs, and the mechanisms leading to treatment failure need to be further investigated. The B-cell lymphoma 2 (BCL-2)-like 11 (BIM) deletion polymorphism, which occurs at a frequency of 21% in East Asians but is absent in African and European populations, has been associated with resistance to first-generation EGFR TKIs, such as gefitinib and erlotinib; and is a poor prognostic factor for NSCLC patients with EGFR mutations...
June 16, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29907768/hmena-isoforms-impact-nsclc-patient-outcome-through-fibronectin-%C3%AE-1-integrin-axis
#12
Francesca Di Modugno, Sheila Spada, Belinda Palermo, Paolo Visca, Pierluigi Iapicca, Anna Di Carlo, Barbara Antoniani, Isabella Sperduti, Anna Di Benedetto, Irene Terrenato, Marcella Mottolese, Francesco Gandolfi, Francesco Facciolo, Emily I Chen, Martin A Schwartz, Angela Santoni, Mina J Bissell, Paola Nisticò
We demonstrated previously that the splicing of the actin regulator, hMENA, generates two alternatively expressed isoforms, hMENA11a and hMENAΔv6, which have opposite functions in cell invasiveness. Their mechanisms of action have remained unclear. Here we report two major findings: (i) hMENA regulates β1 integrin expression. This was shown by depleting total hMENA, which led to loss of nuclear expression of serum response factor (SRF)-coactivator myocardin-related transcription factor 1 (MRTF-A), leading to an increase in the G-actin/F-actin ratio crucial for MRTF-A localization...
June 15, 2018: Oncogene
https://www.readbyqxmd.com/read/29907598/clinical-response-of-the-novel-activating-alk-i1171t-mutation-in-neuroblastoma-to-the-alk-inhibitor-ceritinib
#13
Jikui Guan, Susanne Fransson, Joachim Tetteh T Siaw, Diana Treis, Jimmy Van den Eynden, Damini Chand, Ganesh Umapathy, Petter Svenberg, Kristina Ruuth, Sandra Wessman, Alia Shamikh, Hans Jacobsson, Lena Gordon, Jakob Stenman, Erik Larsson, Par-Johan Svensson, Magnus Hansson, Tommy Martinsson, Per Kogner, Ruth H Palmer, Bengt Hallberg
Tumors with Anaplastic Lymphoma Kinase (ALK) fusion rearrangements, including non-small cell lung cancer and anaplastic large cell lymphoma, are highly sensitive to ALK tyrosine kinase inhibitors (TKIs), underscoring the notion that such cancers are addicted to ALK activity. While mutations in ALK are heavily implicated in childhood neuroblastoma, response to the ALK TKI crizotinib has been disappointing. Embryonal tumors in patients with DNA repair defects such as Fanconi anemia (FA) often have a poor prognosis, due to lack of therapeutic options...
June 15, 2018: Cold Spring Harbor Molecular Case Studies
https://www.readbyqxmd.com/read/29907514/local-control-for-clinical-stage-i-non-small-cell-lung-cancer-treated-with-5-fraction-stereotactic-body-radiation-therapy-is-not-associated-with-treatment-schedule
#14
Pamela Samson, Sana Rehman, Aditya Juloori, Todd DeWees, Michael Roach, Jeffrey Bradley, Gregory M M Videtic, Kevin Stephans, Clifford Robinson
PURPOSE: Clinical concern remains regarding the relationship between consecutive (QD) versus nonconsecutive (QoD) lung stereotactic body radiation therapy (SBRT) treatment schedules and outcomes for clinical stage I non-small cell lung cancer (NSCLC). We examined a multi-institutional series of patients receiving 5-fraction lung SBRT to compare the local failure rates and overall survival between patients receiving QD versus QoD treatment. METHODS AND MATERIALS: Lung SBRT databases from 2 high-volume institutions were combined, and patients receiving 5-fraction SBRT for a solitary stage I NSCLC were identified...
April 10, 2018: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29907488/correlation-of-regional-lung-ventilation-and-gas-transfer-to-red-blood-cells-implications-for-functional-avoidance-radiation-therapy-planning
#15
Leith J Rankine, Ziyi Wang, Bastiaan Driehuys, Lawrence B Marks, Chris R Kelsey, Shiva K Das
PURPOSE: To investigate the degree to which lung ventilation and gas exchange are regionally correlated, using the emerging technology of hyperpolarized (HP)-129 Xe magnetic resonance imaging (MRI). METHODS AND MATERIALS: Hyperpolarized-129 Xe MRI studies were performed on 17 institutional review board-approved human subjects, including 13 healthy volunteers, 1 emphysema patient, and 3 non-small cell lung cancer patients imaged before and approximately 11 weeks after radiation therapy (RT)...
April 14, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29906817/is-immune-checkpoint-inhibition-part-of-standard-therapy-for-stage-iii-non-small-cell-lung-cancer
#16
Jyoti D Patel, Steven J Chmura
No abstract text is available yet for this article.
June 15, 2018: Cancer
https://www.readbyqxmd.com/read/29906749/long-non-coding-rna-linc00339-facilitates-the-tumorigenesis-of-non-small-cell-lung-cancer-by-sponging-mir-145-through-targeting-foxm1
#17
Yuan Yuan, Gao Haiying, Li Zhuo, Lu Ying, He Xin
Non-small cell lung cancer (NSCLC) is one of leading causes of cancer-related death worldwide. Long noncoding RNAs (lncRNAs) has been identified to modulate the tumorigenesis of NSCLC. However, the precise molecular mechanism of lncRNAs in the course is still unclear. Results showed that LINC00339 was significantly up-regulated in NSCLC tissue and cells, which indicated the poor prognosis of NSCLC patients. Loss-of-function experiments showed that LINC00339 silencing inhibited the proliferation and invasion, accelerated the apoptosis, and suppressed the tumor growth of NSCLC cells in vitro and in vivo...
June 12, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29906465/mirna-mediated-apoptosis-activation-through-tmem-48-inhibition-in-a549-cell-line
#18
Feridun Akkafa, İsmail Koyuncu, Ebru Temiz, Hasan Dagli, Fuat Dïlmec, Halit Akbas
Lung has critic function in gas exchange, supplying oxygen to all cells. Rapid metastasis and the high rate of mortality characterises lung cancer. There are two types of this disease, small cell and non-small cell, which differs from each other according to histopathologic features. To date, many therapeutic approaches have been developed to destroy this deadly type of cancer, which one of them is mRNA targeted therapies through miRNA. miRNAs are 19-25 base paired molecules be able to suppress and destruct mRNA and found to be involved in development and progression of lung cancer...
June 12, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29906244/de-novo-lipogenesis-represents-a-therapeutic-target-in-mutant-kras-non-small-cell-lung-cancer
#19
Anju Singh, Christian Ruiz, Kavita Bhalla, John A Haley, Qing Kay Li, George Acquaah-Mensah, Emily Montal, Kuladeep R Sudini, Ferdinandos Skoulidis, Ignacio I Wistuba, Vassiliki Papadimitrakopoulou, John V Heymach, Laszlo G Boros, Edward Gabrielson, Julian Carretero, Kwok-Kin Wong, John D Haley, Shyam Biswal, Geoffrey D Girnun
Oncogenic Kras mutations are one of the most common alterations in non-small cell lung cancer and are associated with poor response to treatment and reduced survival. Driver oncogenes, such as Kras are now appreciated for their ability to promote tumor growth via up-regulation of anabolic pathways. Therefore, we wanted to identify metabolic vulnerabilities in Kras-mutant lung cancer. Using the Kras LSL-G12D lung cancer model, we show that mutant Kras drives a lipogenic gene-expression program. Stable-isotope analysis reveals that mutant Kras promotes de novo fatty acid synthesis in vitro and in vivo...
June 15, 2018: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/29906114/design-synthesis-and-biological-evaluation-of-pyrimido-4-5-d-pyrimidine-2-4-1-h-3-h-diones-as-potent-and-selective-epidermal-growth-factor-receptor-egfr-inhibitors-against-l858r-t790m-resistance-mutation
#20
Yongjia Hao, Jiankun Lyu, Rong Qu, Yi Tong, Deheng Sun, Fang Feng, Linjiang Tong, Tingyuan Yang, Zhenjiang Zhao, Lili Zhu, Jian Ding, Yufang Xu, Hua Xie, Honglin Li
First-generation epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib have achieved initially marked clinical efficacy for non-small cell lung cancer (NSCLC) patients with EGFR activating mutations. However, their clinical benefit was limited by the emergence of acquired resistance mutations. In most cases (approximately 60%), the resistance was caused by the secondary EGFR T790M gatekeeper mutation. Thus, it is still desirable to develop novel third-generation EGFR inhibitors to overcome T790M mutation while sparing wild-type (WT) EGFR...
June 15, 2018: Journal of Medicinal Chemistry
keyword
keyword
15685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"